FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3214602761> ?p ?o ?g. }

• W3214602761 abstract "Aim: Anti-angiogenesis agents have been added as maintenance therapy in ovarian cancer over the past decade. The aim of this meta-analysis was to analyze the efficacy of anti-angiogenesis therapy in newly diagnosed and relapsed ovarian cancer. Methods: PubMed, Embase, and Cochrane databases were searched for all phase III randomized controlled trials (RCTs) that assessed the efficacy and toxicity of anti-angiogenesis agents in ovarian cancer. Overall survival (OS) and progression-free survival (PFS) were used to evaluate the effectiveness of anti-angiogenesis therapy in ovarian cancer. Results: A total of 6097 patients with newly diagnosed ovarian cancer from 5 phase III RCTs and 2943 patients with relapsed ovarian cancer from 6 phase III RCTs were included in this meta-analysis. The pooled results showed that anti-angiogenesis maintenance therapy significantly improved PFS (hazard ratio [HR], 0.84; 95% confidence interval [CI], 0.76-0.93; p = 0.001), but not OS (HR, 0.98; 95% CI, 0.91-1.05; p = 0.49) compared with placebo in patients with newly diagnosed ovarian cancer. In patients with relapsed ovarian cancer, the pooled results showed a significant improvement on OS (HR, 0.89; 95% CI, 0.82-0.98; p = 0.02) and PFS (HR, 0.61; 95% CI, 0.52-0.72; p < 0.001). The pooled results also showed that the anti-angiogenesis agents were associated with an increase in the occurrence of severe hypertension, neutropenia, diarrhea, thrombocytopenia, headache, and bleeding in ovarian cancer. However, infrequent fatal adverse events occurred in the anti-angiogenesis groups. Conclusions: Study results suggest that anti-angiogenesis agents were an effective therapy for newly diagnosed and relapsed ovarian cancer, especially for relapsed ovarian cancer. Anti-angiogenesis agents may be associated with some severe but not fatal adverse events. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42021283647." @default.
• W3214602761 created "2021-11-22" @default.
• W3214602761 creator A5036813984 @default.
• W3214602761 creator A5038261237 @default.
• W3214602761 creator A5038813533 @default.
• W3214602761 creator A5065301971 @default.
• W3214602761 creator A5080455671 @default.
• W3214602761 date "2021-11-17" @default.
• W3214602761 modified "2023-10-16" @default.
• W3214602761 title "Anti-Angiogenesis Maintenance Therapy in Newly Diagnosed and Relapsed Ovarian Cancer: A Meta-analysis of Phase III Randomized Controlled Trials" @default.
• W3214602761 cites W1793338775 @default.
• W3214602761 cites W1852968667 @default.
• W3214602761 cites W1964435302 @default.
• W3214602761 cites W1966746890 @default.
• W3214602761 cites W1974218755 @default.
• W3214602761 cites W1985599020 @default.
• W3214602761 cites W1987219093 @default.
• W3214602761 cites W2002735814 @default.
• W3214602761 cites W2068854353 @default.
• W3214602761 cites W2098923148 @default.
• W3214602761 cites W2102195694 @default.
• W3214602761 cites W2102306754 @default.
• W3214602761 cites W2107328434 @default.
• W3214602761 cites W2111636520 @default.
• W3214602761 cites W2113122060 @default.
• W3214602761 cites W2120022879 @default.
• W3214602761 cites W2125435699 @default.
• W3214602761 cites W2133537644 @default.
• W3214602761 cites W2135947389 @default.
• W3214602761 cites W2146878122 @default.
• W3214602761 cites W2157823046 @default.
• W3214602761 cites W2165143139 @default.
• W3214602761 cites W2170552969 @default.
• W3214602761 cites W2170928115 @default.
• W3214602761 cites W2171658624 @default.
• W3214602761 cites W2200887263 @default.
• W3214602761 cites W2255518001 @default.
• W3214602761 cites W2293618284 @default.
• W3214602761 cites W2293809486 @default.
• W3214602761 cites W2344322811 @default.
• W3214602761 cites W2518249527 @default.
• W3214602761 cites W2550685071 @default.
• W3214602761 cites W2551627255 @default.
• W3214602761 cites W2558389544 @default.
• W3214602761 cites W2593027991 @default.
• W3214602761 cites W2605456582 @default.
• W3214602761 cites W2745818077 @default.
• W3214602761 cites W2748207273 @default.
• W3214602761 cites W2767472502 @default.
• W3214602761 cites W2769621927 @default.
• W3214602761 cites W2899227888 @default.
• W3214602761 cites W2900961083 @default.
• W3214602761 cites W2936836467 @default.
• W3214602761 cites W2943864790 @default.
• W3214602761 cites W2945458218 @default.
• W3214602761 cites W2951714360 @default.
• W3214602761 cites W2965546441 @default.
• W3214602761 cites W2972811117 @default.
• W3214602761 cites W2980121911 @default.
• W3214602761 cites W3002231793 @default.
• W3214602761 cites W3028607434 @default.
• W3214602761 cites W3028739923 @default.
• W3214602761 cites W3119005666 @default.
• W3214602761 doi "https://doi.org/10.3389/fphar.2021.726278" @default.
• W3214602761 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34867330" @default.
• W3214602761 hasPublicationYear "2021" @default.
• W3214602761 type Work @default.
• W3214602761 sameAs 3214602761 @default.
• W3214602761 citedByCount "1" @default.
• W3214602761 countsByYear W32146027612023 @default.
• W3214602761 crossrefType "journal-article" @default.
• W3214602761 hasAuthorship W3214602761A5036813984 @default.
• W3214602761 hasAuthorship W3214602761A5038261237 @default.
• W3214602761 hasAuthorship W3214602761A5038813533 @default.
• W3214602761 hasAuthorship W3214602761A5065301971 @default.
• W3214602761 hasAuthorship W3214602761A5080455671 @default.
• W3214602761 hasBestOaLocation W32146027611 @default.
• W3214602761 hasConcept C121608353 @default.
• W3214602761 hasConcept C126322002 @default.
• W3214602761 hasConcept C142724271 @default.
• W3214602761 hasConcept C143998085 @default.
• W3214602761 hasConcept C168563851 @default.
• W3214602761 hasConcept C197934379 @default.
• W3214602761 hasConcept C204787440 @default.
• W3214602761 hasConcept C207103383 @default.
• W3214602761 hasConcept C27081682 @default.
• W3214602761 hasConcept C2776694085 @default.
• W3214602761 hasConcept C2776999253 @default.
• W3214602761 hasConcept C2777063308 @default.
• W3214602761 hasConcept C2777802072 @default.
• W3214602761 hasConcept C2778283404 @default.
• W3214602761 hasConcept C2780394083 @default.
• W3214602761 hasConcept C2780427987 @default.
• W3214602761 hasConcept C2780739268 @default.
• W3214602761 hasConcept C44249647 @default.
• W3214602761 hasConcept C71924100 @default.
• W3214602761 hasConcept C95190672 @default.
• W3214602761 hasConceptScore W3214602761C121608353 @default.
• W3214602761 hasConceptScore W3214602761C126322002 @default.
• W3214602761 hasConceptScore W3214602761C142724271 @default.

• next